SciClone Pharmaceuticals (Holdings) Ltd is a company principally engaged in the provision of treatment plans for tumors and severe infectious diseases. The Company and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Companyâs main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Companyâs pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Companyâs products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The Company mainly conducts its businesses in the domestic market.
More about the company